{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:35:26Z","timestamp":1787636126095,"version":"build-2736575974"},"reference-count":45,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2026,5,16]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Shorter dual antiplatelet therapy (DAPT) regimens may offer a more favourable risk-benefit profile compared with longer treatment. The aim of this study was to determine the optimal duration by assessing net adverse clinical events (NACE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched for randomised controlled trials that compared clinical outcomes of different DAPT durations in patients with ischaemic heart disease from Medline, Scopus and the Cochrane Library. A network meta-analysis was subsequently conducted for DAPT durations of 1 month, 3 months, 6 months, 12 months and &gt;12 months. The primary outcome was defined as NACE, a composite of death, myocardial infarction, stroke, stent thrombosis and bleeding events. Individual components of NACE served as secondary outcomes. Five DAPT durations were ranked for each outcome using surface under the cumulative ranking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis included 31 randomised controlled trials comprising 95\u2009910 patients. 1-month DAPT was associated with a significantly lower risk of NACE compared with 3-month, 6-month, 12-month and &gt;12\u2009month DAPT (risk ratio (CI): 0.74 (0.58 to 0.93); 0.63 (0.50 to 0.80); 0.64 (0.53 to 0.78); and 0.67 (0.51 to 0.87), respectively). There were no significant differences in death, myocardial infarction, stroke or stent thrombosis with 1-month DAPT, except for a higher risk of myocardial infarction compared with &gt;12\u2009month DAPT (risk ratio (CI): 1.53 (1.02 to 2.30)). Notably, 1-month DAPT was associated with a significantly lower risk of bleeding events compared with 12-month and &gt;12\u2009month DAPT (risk ratio (CI): 0.57 (0.40 to 0.83)\u2009and 0.47 (0.29 to 0.77), respectively). The SUCRA value for NACE was the highest for the 1-month regimen (99.8, 65.4, 24.6, 21.9 and 38.3 for 1 month, 3 months, 6 months, 12 months and &gt;12 months, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>1-month DAPT may offer the lowest risk balance between ischaemic and bleeding risks; however, these findings should be applied within an individualised, patient-specific risk management framework.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/heartjnl-2025-327720","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:20:15Z","timestamp":1780334415000},"page":"heartjnl-2025-327720","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal duration of dual antiplatelet therapy in ischaemic heart disease: a systematic review and network meta-analysis of randomised controlled trials"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-3051","authenticated-orcid":false,"given":"Toshiharu","family":"Fujii","sequence":"first","affiliation":[{"name":"Cardiovascular Medicine, Tokai University School of Medicine, Isehara, Japan"},{"name":"Cardiovascular Medicine, Tokai University Hachioji Hospital, Hachioji, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Tokai University Hachioji Hospital, Hachioji, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yota","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Tokai University Hachioji Hospital, Hachioji, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Okutsu","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Tokai University Hachioji Hospital, Hachioji, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminobu","family":"Yoshimachi","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Tokai University Hachioji Hospital, Hachioji, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikari","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Tokai University School of Medicine, Isehara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026060110201237000_heartjnl-2025-327720v1.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"2026060110201237000_heartjnl-2025-327720v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae177"},{"key":"2026060110201237000_heartjnl-2025-327720v1.3","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2026060110201237000_heartjnl-2025-327720v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392303"},{"key":"2026060110201237000_heartjnl-2025-327720v1.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026060110201237000_heartjnl-2025-327720v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"2026060110201237000_heartjnl-2025-327720v1.7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"2026060110201237000_heartjnl-2025-327720v1.8","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500403"},{"key":"2026060110201237000_heartjnl-2025-327720v1.9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"2026060110201237000_heartjnl-2025-327720v1.10","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"2026060110201237000_heartjnl-2025-327720v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.07.005"},{"key":"2026060110201237000_heartjnl-2025-327720v1.12","unstructured":"Higgins J , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions. 2nd edn. Cochrane Learning, 2023."},{"key":"2026060110201237000_heartjnl-2025-327720v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"2026060110201237000_heartjnl-2025-327720v1.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"2026060110201237000_heartjnl-2025-327720v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.08.034"},{"key":"2026060110201237000_heartjnl-2025-327720v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31858-0"},{"key":"2026060110201237000_heartjnl-2025-327720v1.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.8145"},{"key":"2026060110201237000_heartjnl-2025-327720v1.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108749"},{"key":"2026060110201237000_heartjnl-2025-327720v1.19","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026060110201237000_heartjnl-2025-327720v1.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066943"},{"key":"2026060110201237000_heartjnl-2025-327720v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00473-2"},{"key":"2026060110201237000_heartjnl-2025-327720v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.043"},{"key":"2026060110201237000_heartjnl-2025-327720v1.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282183"},{"key":"2026060110201237000_heartjnl-2025-327720v1.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.8146"},{"key":"2026060110201237000_heartjnl-2025-327720v1.25","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-19-00539"},{"key":"2026060110201237000_heartjnl-2025-327720v1.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908419"},{"key":"2026060110201237000_heartjnl-2025-327720v1.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7580"},{"key":"2026060110201237000_heartjnl-2025-327720v1.28","first-page":"E653","article-title":"Efficacy and Safety of 3 Versus 6 Months of Dual-Antiplatelet Therapy in Patients Implanted With a Coroflex ISAR Stents: A Prospective, Multicenter","volume":"34","author":"Jin","year":"2022","journal-title":"Randomized Clinical Trial J Invasive Cardiol"},{"key":"2026060110201237000_heartjnl-2025-327720v1.29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0877","article-title":"P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial","volume":"7","author":"Min","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026060110201237000_heartjnl-2025-327720v1.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.059022"},{"key":"2026060110201237000_heartjnl-2025-327720v1.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.071589"},{"key":"2026060110201237000_heartjnl-2025-327720v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.008"},{"key":"2026060110201237000_heartjnl-2025-327720v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.11.008"},{"key":"2026060110201237000_heartjnl-2025-327720v1.34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu523"},{"key":"2026060110201237000_heartjnl-2025-327720v1.35","first-page":"1438","article-title":"6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation","volume":"9","author":"Hong","year":"2016","journal-title":"JACC: Cardiovascular Interventions"},{"key":"2026060110201237000_heartjnl-2025-327720v1.36","first-page":"555","article-title":"Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial","volume":"89","author":"Qi","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026060110201237000_heartjnl-2025-327720v1.37","first-page":"1189","article-title":"Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC: Cardiovascular Interventions"},{"key":"2026060110201237000_heartjnl-2025-327720v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30493-8"},{"key":"2026060110201237000_heartjnl-2025-327720v1.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"key":"2026060110201237000_heartjnl-2025-327720v1.40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003303"},{"key":"2026060110201237000_heartjnl-2025-327720v1.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312"},{"key":"2026060110201237000_heartjnl-2025-327720v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60612-7"},{"key":"2026060110201237000_heartjnl-2025-327720v1.43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv481"},{"key":"2026060110201237000_heartjnl-2025-327720v1.44","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003663","article-title":"Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study","volume":"95","author":"Dadjou","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026060110201237000_heartjnl-2025-327720v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00901-2"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2025-327720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:20:18Z","timestamp":1780334418000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2025-327720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":45,"alternative-id":["10.1136\/heartjnl-2025-327720"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2025-327720","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}